10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT

Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki · 2023

Read 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT by Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10710578.txt.

Description

Toshihide Tanaka and co-authors report a trial of drug treatment given before surgery for a harsh brain tumor, in a paper from 2023. The tumor type is malignant glioma, most often glioblastoma. One drug, bevacizumab, is standard before surgery in bowel cancer but not in brain tumors. The multi-center trial tested safety first, then looked for signs of gain.

Fifteen patients got the drug plus a chemo pill before their operations. Surgery followed about three weeks later. Two patients had severe side effects tied to the drugs, such as wound infection and low blood counts. Tumors shrank in nearly all cases, and patient function scores improved before surgery. Average time before the disease grew again was about nine and a half months. The authors call the plan safe and worth study for some patients.

Catalog record

CREATORToshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Keisuke Miyake, Hikaru Sasaki
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10710578

Browse the full library · About the Tower of Babel